915030-08-9

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
2-(TRIFLUOROMETHYL)-1,3-THIAZOLE-4-CARBOXYLIC ACID is used as a chemical intermediate for the synthesis of various pharmaceutical compounds due to its potential to exhibit a range of biological activities. Its anti-bacterial properties make it suitable for the development of new antibiotics, while its anti-cancer and anti-inflammatory activities suggest its use in the creation of novel therapeutic agents for cancer treatment and inflammatory conditions, respectively.
Used in the Development of Antibiotics:
In the field of antibiotic development, 2-(TRIFLUOROMETHYL)-1,3-THIAZOLE-4-CARBOXYLIC ACID is utilized as a key component in the synthesis of new antimicrobial agents. Its anti-bacterial properties contribute to the design of drugs that can combat resistant bacterial strains, addressing the growing need for effective treatments in the face of antibiotic resistance.
Used in Cancer Treatment:
2-(TRIFLUOROMETHYL)-1,3-THIAZOLE-4-CARBOXYLIC ACID is employed as a potential anti-cancer agent in the pharmaceutical industry. Its ability to target and inhibit the growth of cancer cells makes it a valuable compound in the development of novel cancer therapies, offering new treatment options for patients with various types of cancer.
Used in Anti-Inflammatory Therapies:
In the realm of anti-inflammatory drug development, 2-(TRIFLUOROMETHYL)-1,3-THIAZOLE-4-CARBOXYLIC ACID is used as a starting material for the creation of new medications aimed at reducing inflammation and alleviating symptoms associated with inflammatory diseases. Its anti-inflammatory properties provide a foundation for the design of drugs that can effectively manage chronic inflammatory conditions.

InChI:InChI=1/C5H2F3NO2S/c6-5(7,8)4-9-2(1-12-4)3(10)11/h1H,(H,10,11)

Upstream product

• 133046-46-5 Ethyl 2-(trifluoromethyl)thiazole-4-carboxylate 

Relevant academic research and scientific papers

ANDROGEN RECEPTOR MODULATING COMPOUNDS

Compounds of formula (I) wherein R1 to R16, A. B and E are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as tissue-selective androgen receptor modulators (SARM) and are particularly useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.

Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors

The invention provides a compound of formula (I) or a salt thereof: wherein R2 is H, C1-3alkyl, n-butyl, C1-2fluoroalkyl, cyclopropyl, cyclobutyl, (cyclopropyl)methyl-, —CN, or —CH2OH; R3 is inter alia optionally substituted C4-7cycloalkyl or an optionally substituted heterocyclic group (aa), (bb) or (cc); Ra is H, methyl or ethyl; Rb is H or methyl; R4 is H, methyl, ethyl, n-propyl, —C(O)-Me, or —C(O)—C1fluoroalkyl; and R5 is: —C(O)—(CH2)n—Ar, —C(O)-Het, —C(O)—C1-6alkyl, —C(O)—C1 fluoroalkyl, —C(O)—(CH2)2—C(O)—NR15bNR15b, —C(O)—CH2—C(O)—NR15bNR15b, —C(O)—NR15b—(CH2)m1—Ar, —C(O)—NR15b—Het, —C(O)—NR15b—C1-6alkyl, —C(O)—NR5aR5b, —S(O)2—(CH2)m2—Ar, —S(O)2-Het, —S(O)2—C1-6alkyl, or —CH2—Ar; or R4 and R5 taken together are —(CH2)p1—, —(CH2)2—X5—(CH2)2—, —C(O)—(CH2)p2—, —C(O)—N(R15)—(CH2)p3—; or NR4R5 is of sub-formula (y), (y1), (y2) or (y3). The invention provides the use of the compounds as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as COPD and the like.

BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS

The invention provides a compound of formula (I) or a salt thereof: wherein R2 is H, C1-3alkyl, n butyl, C1-2fluoroalkyl, cyclopropyl, cyclobutyl, (cyclopropyl)methyl , CN, or CH2OH; R3 is inter alia optionally substituted C4-7cycloalkyl or an optionally substituted heterocyclic group (aa), (bb) or (cc); Ra is H, methyl or ethyl; Rb is H or methyl; R4 is H, methyl, ethyl, n propyl, C(O) Me, or C(O) C1fluoroalkyl; and R5 is: C(O) (CH2)n Ar, C(O) Het, C(O) C1 6alkyl, C(O) C1fluoroalkyl, C(O) (CH2)2 C(O) NR15bNR15b, C(O) CH2 C(O) NR15bNR15b, C(O) NR15b (CH2)m1 Ar, C(O) NR15b Het, C(O) NR15b C1-6 alkyl, C(O) NR5aR5b, S(O)2 (CH2)m2-Ar, S(O)2 Het, S(O)2-C1-6alkyl, or CH2 Ar; or R4 and R5 taken together are-(CH2)p1-, (CH2)2 X5 (CH2)2 , C(O) (CH2)p2 ,-C(O)-N(R15) (CH2)p3 ; or NR4R5 is of sub-formula (y), (y1), (y2) or (y3). The invention also provides the use of the compounds as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, allergic rhinitis, psoriasis or atopic dermatitis.

2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES MODULATING THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1)

The use of a compound of formula (I): for the manufacture of a medicament for the treatment of conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1, also known as TRPV1).